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Objective. To determine the mortality rate and its predictors 
in patients with a presumptive diagnosis of tuberculous 
pericarditis in sub-Saharan Africa.
Design. Between 1 March 2004 and 31 October 2004, we 
enrolled 185 consecutive patients with presumed tuberculous 
pericarditis from 15 referral hospitals in Cameroon, Nigeria 
and South Africa, and observed them during the 6-month 
course of antituberculosis treatment for the major outcome of 
mortality. This was an observational study, with the diagnosis 
and management of each patient left at the discretion of the 
attending physician. Using Cox regression, we have assessed 
the effect of clinical and therapeutic characteristics (recorded at 
baseline) on mortality during follow-up.
Results. We obtained the vital status of 174 (94%) patients 
(median age 33; range 14 - 87 years). The overall mortality rate 
was 26%. Mortality was higher in patients who had clinical 
features of HIV infection than in those who did not (40% v. 
17%, p=0.001). Independent predictors of death during follow-
up were: (i) a proven non-tuberculosis final diagnosis (hazard 
ratio (HR) 5.35, 95% confidence interval (CI) 1.76 - 16.25), (ii) 
the presence of clinical signs of HIV infection (HR 2.28, CI 
1.14 - 4.56), (iii) coexistent pulmonary tuberculosis (HR 2.33, CI 
1.20 - 4.54), and (iv) older age (HR 1.02, CI 1.01 - 1.05). There 
was also a trend towards an increase in death rate in patients 
with haemodynamic instability (HR 1.80, CI 0.90 - 3.58) and a 
decrease in those who underwent pericardiocentesis (HR 0.34, 
CI 0.10 - 1.19).
Conclusion. A presumptive diagnosis of tuberculous pericarditis 
is associated with a high mortality in sub-Saharan Africa. 
Attention to rapid aetiological diagnosis of pericardial effusion 
and treatment of concomitant HIV infection may reduce the 
high mortality associated with the disease.
S Afr Med J 2008; 98: 36-40.
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Tuberculous pericarditis is one of the most severe forms of 
extrapulmonary tuberculosis, causing death or disability in 
a substantial proportion of affected people.1,2 In Africa, the 
incidence of tuberculous pericarditis is rising as a result of 
the HIV epidemic.3 The effect of HIV infection on survival in 
patients with tuberculous pericarditis is unknown.2,4 Whereas 
some investigators have suggested that HIV-infected patients 
with tuberculous pericarditis have a similar outcome to 
non-infected cases,5 others have shown that there may be 
an increase in mortality in HIV associated with tuberculous 
pericarditis.2,6,7 We established a prospective observational 
study, the Investigation of the Management of Pericarditis in 
Africa (IMPI Africa) registry, to obtain current information 
on the diagnosis, management and outcome of patients with 
presumed tuberculous pericarditis living in sub-Saharan 
Africa, where the burden of HIV infection is the greatest in the 
world.4,8-10 In this paper, we report the mortality rate and its 
predictors during the 6 months of antituberculosis treatment 
among patients enrolled in the registry.
Methods
The IMPI Africa registry was a multi-centre, prospective, 
cohort study of consecutive patients treated for tuberculous 
pericarditis in 15 referral hospitals in Cameroon, Nigeria and 
South Africa (SA). The design and conduct of the registry has 
been described in detail elsewhere.4  The study was approved 
by the Research Ethics Committee of the University of Cape 
Town, and all participants gave written informed consent.
The participants were recruited between 1 March 2004 and 
31 October 2004. Consecutive incident cases of suspected 
tuberculous pericarditis were recruited on commencement 
of antituberculosis treatment. Patients were eligible for 
enrolment if the attending physician felt sufficiently confident 
with the diagnosis of tuberculous pericarditis to commence 
antituberculosis treatment. The diagnosis and management of 
each patient was at the discretion of the attending physician 
in keeping with the observational nature of the study. The 
HIV status was based on the results of the serological test 
for HIV. However, at the time of the study, voluntary and 
confidential testing for HIV was not always offered in all 
medical institutions in Africa. We therefore requested the 
physicians to state whether they suspected HIV infection on 
clinical grounds and to classify each patient (on enrolment) as 
either having evidence of ‘clinical HIV disease’ or ‘no clinical 
HIV disease’ without regard to the HIV serological status of 
the patient. This assessment was left to the discretion of the 
collaborating physician, and no criteria were specified. This 
approach is consistent with usual clinical practice in Africa 
where, because of resource constraints, the diagnosis of 
tuberculous pericarditis is often made on clinical grounds,2 and 
clinical criteria for the assessment of HIV status are used in 
routine practice.11 No guidance on diagnosis and management 
was provided to the physicians because, as indicated earlier, 
one of the aims of the registry was to document contemporary 
practice regarding diagnosis and treatment of tuberculous 
pericarditis among physicians in various regions of sub-
Saharan Africa.
Clinical and therapeutic data on each patient were recorded 
on standardised case record forms – on enrolment and at 3 
and 6 months following enrolment – and sent to the Project 
Co-ordinating Office at the University of Cape Town. Patient 
follow-up was carried out by personal interview, failing 
which telephonic enquiry and postal services were used. On 
enrolment, each patient nominated a person who could be 
contacted if the patient was unreachable at the time of follow-
up. We also used the services of the South African Department 
of Home Affairs (for South African centres) and a private 
detective company to obtain the vital status of patients lost to 
follow-up. Study follow-up ended on 30 April 2005.
Statistical analysis was conducted with the STATA 9.0 
package (STATA Corporation, College Station, Texas). We 
used the Kaplan-Meier method to display the mortality rate, 
and the log-rank test to compare the survival distributions 
between patients with clinical features of HIV infection (or 
‘clinical HIV disease’) and those without. Cox proportional 
hazards regression was used to determine which pre-
defined characteristics (i.e. age, gender, clinical HIV disease, 
serologically confirmed HIV infection, pulmonary tuberculosis, 
abnormal electrocardiogram, haemodynamic instability, New 
York Heart Association (NYHA) functional impairment, 
alternative diagnosis, pericardiocentesis, adjunctive steroid 
use, geographical region, and antiretroviral drug use) were 
associated with mortality. Clinical HIV disease and serological 
HIV infection were fitted into separate multivariate regression 
models. We grouped the 15 participating hospitals into 
6 geographical regions, viz. Eastern Cape (SA), Gauteng 
(SA), KwaZulu-Natal (SA), Western Cape (SA), Yaoundé 
(Cameroon), and Ibadan (Nigeria). Geographical region was 
fitted into the multivariate regression model as an explanatory 
variable, with Eastern Cape (SA) as the reference group (i.e. the 
region that contributed the largest number of patients to the 
study). The data reported are medians (ranges), absolute counts 
(percentages), and hazard ratios (HR) with 95% confidence 
intervals (CI). Significance tests were two-tailed, and statistical 
significance was defined at the 5% alpha level.
Results
We obtained complete survival information for 174 of the 
185 (i.e. 94%) enrolled participants, whose characteristics are 
shown in Table I. The 11 patients (6%) who did not come for 
follow-up visits and for whom we could not obtain information 
on vital status (at 6 months from enrolment) were from Ibadan 
(N=1), the Western Cape (N=1), Guateng (N=2), KwaZulu-
Natal (N=3), and the Eastern Cape (N=4). The median age 
of the 174 patients with complete information was 33 years 
(range 14 - 87 years), 57% were men, and 39% had clinical HIV 
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disease. Ninety-six (52%) patients had a serological test for HIV 
infection, and 53 of these (55%) were found to be HIV positive. 
There was strong agreement between clinical signs of HIV 
disease and serological HIV status, which confirms the validity 
of the clinical assessment of HIV status in this study.4,11 The 
sensitivity of clinical signs of HIV disease was 76% (40/53) and 
the specificity 88% (38/43). One hundred and sixty-eight (97%) 
had definite or probable tuberculous pericarditis, according 
to the criteria of Mayosi et al.2 All patients were commenced 
on antituberculosis chemotherapy, and 102 (59%) received 
adjunctive oral corticosteroids. At baseline, 7 of 53 (13%) 
patients with serologically confirmed HIV infection were on 
antiretroviral drugs, and by 6 months the number had risen 
to 10 (19%). Six patients (3%) had a proven non-tuberculosis 
cause for pericarditis (i.e. malignancy, 2; purulent pericarditis, 
2; nephrotic syndrome, 1; systemic lupus erythematosus, 1). 
Overall, the 174 patients with complete follow-up information 
were representative of the 185 enrolled in the study (Table I).
The overall mortality rate at 6 months was 26%; 40% in 
patients with clinical HIV disease and 17% in those without 
(p=0.001). The Kaplan-Meier survival distributions for patients 
with and without clinical HIV disease show that at any point 
during follow-up, patients with clinical signs of HIV infection 
had a significantly higher mortality rate than those without 
clinical evidence of HIV disease (crude log rank χ2=10.72; df=1; 
p=0.001) (Fig. 1).
Univariate Cox proportional hazards regression analyses 
identified age (p=0.019), clinical HIV disease (p=0.002), 
pulmonary tuberculosis (p=0.009), a proven non-tuberculosis 
cause of pericarditis (p=0.007), use of antiretroviral drugs 
(p=0.003), and residence in Yaoundé, Cameroon (p<0.001) to 
be significantly associated with a higher mortality rate during 
follow-up (Table II). The results remained unchanged when 
the univariate analyses was repeated, controlling for age. In 
addition, there was a marginally significant increase in death 
rate among patients who presented with dyspnoea (p=0.079) 
and haemodynamic instability (p=0.094), and a decrease in 
those who received adjunctive steroids (p=0.058).
In the multivariate Cox regression model, the independent 
predictors of mortality (Table III) were a proven non-
tuberculosis diagnosis (HR 5.35, 95% CI 1.76 - 16.25), presence 
of clinical features of HIV infection (HR 2.28, 95% CI 1.14 
- 4.56), pulmonary tuberculosis (HR 2.33, 95% CI 1.20 - 4.54), 
and increasing age (HR 1.02, 95% CI 1.01 - 1.05). There was 
also a trend towards an increase in mortality in patients 
with haemodynamic instability (HR 1.80, CI 0.90 - 3.58) and 
a decrease in those who underwent pericardiocentesis (HR 
0.34, CI 0.10 - 1.19). When we excluded the 6 patients with a 
non-tuberculous cause of pericarditis, the results remained 
unchanged.
Discussion
We found, in the first multi-centre study of mortality in 
pericardial disease, that 26% of patients with presumed 
pericardial tuberculosis die within 6 months of diagnosis, 
despite antituberculosis therapy. Clinically evident HIV 
infection had a major impact on the death rate, raising it from 
17% in patients without clinical features of HIV infection 
to 40% in those with overt HIV disease. Other predictors 
of mortality were a non-tuberculous cause of pericarditis, 
Table I. Comparison of characteristics of the original patient population and those included in the survival analysis
    Original sample   Survival analysis
Variable    N=185    N=174
Age (years)   33 (14 - 87 yrs)   33 (14 - 87 yrs)
Men    103 (55.7%)    99 (56.9%)
Clinical HIV   74 (40.0%)     68 (39.1%)
HIV seropositive   53 (55.2%)     51 (54.8%)
Pulmonary tuberculosis  48 (26.8%)     46 (27.2%)
Abnormal ECG     92 (77.3%)     85 (76.6%)
Haemodynamic instability*  54 (29.2%)     50 (28.7%)
Pericardiocentesis     26 (14.1%)     26 (14.9%)
Dyspnoea (NYHA classes II - IV) 146 (78.9%)   135 (77.6%)
Alternative diagnosis  6 (3.2%)    6  (3.4%)
Antiretroviral drug use  10 (18.9%)   10 (19.6%)
Adjunctive steroid use  109 (58.9%)   102 (58.6%)
Geographical region  
Yaoundé (Cameroon)  17 (9.2%)      17 (9.8%)
Ibadan (Nigeria)   31 (16.8%)     30 (17.2%)
Eastern Cape (South Africa)   58 (31.4%)     54 (31.0%)
Gauteng (South Africa)    21 (11.4%)     19 (10.9%)
KwaZulu-Natal (South Africa) 23 (12.4%)     20 (11.5%)
Western Cape (South Africa) 35 (18.9%)     34 (19.5%)
Values are median (range) or absolute counts (percentage). Denominators differ due to missing values.  
*Pulse rate >100 beats per minute, systolic blood pressure <100 mmHg and/or tamponade requiring pericardiocentesis. 
NYHA = New York Heart Association classification of functional status.
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pulmonary tuberculosis (a marker of disseminated disease), 
and, as expected, increasing age.
The introduction of antituberculosis chemotherapy 
resulted in dramatic reduction in mortality from tuberculous 
pericarditis from 80% in the 1950s to 8% by the 1980s.2,12 
The extremely high 6-month all-cause mortality in this 
cohort of relatively young patients (median age 33 years) is 
approximately equivalent to the 10-year all-cause mortality 
reported in patients with pericardial effusion in the only large 
survival study of tuberculous pericarditis reported from pre-
HIV Africa.13 Bearing in mind the impact of age on mortality, 
the difference is even more striking, given that the median 
age of patients in the 10-year series13  was more than a decade 
older than those of our patients. The dramatic deterioration in 
outcome of patients with suspected tuberculous pericarditis 
that we observed has been associated with the advent of the 
HIV epidemic.
Table III.  Multivariate Cox proportional hazards regression analyses for time to death
                All 174 patients  Excluding the 6 patients with alternative diagnoses
Baseline characteristic  HR 95% CI          p   HR 95% CI          p
Age    1.02 1.01 - 1.05          0.012  1.02 1.00 - 1.05          0.050
Men    1.67 0.88 - 3.15          0.114  1.55    0.81 - 2.96          0.189
Clinical HIV disease  2.28 1.14 - 4.56          0.001  2.03 1.00 - 4.11          0.050
Pulmonary tuberculosis  2.33 1.20 - 4.54          0.013  2.78 1.41 - 5.48          0.003
Haemodynamic instability  1.80 0.90 - 3.58          0.095  1.50 0.73 - 3.12          0.272
Dyspnoea   1.20 0.44 - 3.27          0.717  1.09 0.39 - 2.99          0.872
Alternative diagnosis  5.35 1.76 - 16.25        0.003     –        –             –
Pericardiocentesis   0.34 0.10 - 1.19          0.092  0.27 0.06 - 1.21          0.087
Adjunctive steroid use  0.84 0.45 - 1.58          0.595  0.76 0.40 - 1.47          0.420
HR = hazard ratio; CI = confidence interval; p = the probability that the effect of the characteristic on the time to death in this study occurred by chance alone, given that there is truly 
no relationship between the characteristic and survival.
Table II. Univariate Cox proportional hazards regression analyses for time to death
           Univariate analysis              Univariate analysis, controlling for age
Baseline characteristic  HR 95% CI        p   HR 95% CI        p
Age    1.02 1.01 - 1.04        0.019     –        –           –
Men    1.50 0.81 - 2.76        0.194       1.50 0.82 - 2.76        0.192     
Clinical HIV disease  2.61 1.44 - 4.74        0.002       2.60 1.43 - 4.73        0.002     
HIV seropositive   1.35 0.63 - 2.88        0.437       1.56 0.70 - 3.46        0.274      
Pulmonary tuberculosis  2.22 1.22 - 4.05        0.009   2.51   1.36 - 4.65        0.003      
Abnormal electrocardiogram  0.62 0.28 - 1.36        0.232       0.65     0.29 - 1.42        0.280     
Haemodynamic instability  1.65 0.90 - 3.01        0.104        1.67   0.92 - 3.06        0.094     
Dyspnoea   2.34 0.93 - 5.95        0.072       2.30   0.91 - 5.84        0.079     
Alternate diagnosis   4.16 1.49 - 11.63      0.007   4.12    1.47 - 11.52      0.007     
Pericardiocentesis   0.39   0.12 - 1.26        0.115       0.41   0.13 - 1.31        0.133     
Adjunctive steroid use  0.61 0.34 - 1.10        0.098       0.57    0.31 - 1.02        0.058     
Antiretroviral drugs  4.31 1.59 - 11.68      0.004   3.66 1.30 - 10.32      0.014
Gauteng    0.84 0.28 - 2.59        0.768   0.90 0.29 - 2.78        0.861
KwaZulu-Natal   0.36 0.08 - 1.61        0.184   0.41 0.09 - 1.83        0.241
Western Cape   0.74 0.28 - 1.95        0.543   0.82 0.31 - 2.18        0.692
Ibadan    1.31    0.56 - 3.06        0.535       1.41  0.60 - 3.31        0.432    
Yaoundé    4.63   2.07 - 10.35     <0.001  4.63   2.07 - 10.37     <0.001
HR = hazard ratio; CI = confidence interval; p = the probability that the effect of the characteristic on the time to death in this study occurred by chance alone, given that there is truly 
no relationship between the characteristic and survival.
39
Fig. 1. Survival during follow-up in the whole study 
population and by clinical HIV status (p=0.001 for the 
difference in survival experiences between groups defined by 
clinical status).
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We have previously shown that patients with suspected 
tuberculous pericarditis and HIV infection have greater 
myocardial involvement, dyspnoea and haemodynamic 
instability.4 There was a trend towards an independent 
association between these factors and mortality in multivariate 
analysis, which did not attain statistical significance, and 
it is likely that these factors are markers of severe cardiac 
disease which would be expected to have a negative effect on 
mortality. However, the hazard ratios for these factors had 
wide confidence intervals, and it is possible that our study did 
not have adequate statistical power to detect an effect of the 
magnitude observed.
The 12-month mortality of HIV-seropositive patients with 
extrapulmonary tuberculosis is 22 - 25%, which suggests that 
the mortality rate of 40% at 6 months in people with clinical 
overt HIV disease is exceptionally high.14 It is of interest 
that the use of adjunctive oral corticosteroids in 59% of the 
participants4 (a controversial intervention in this condition6,15,16) 
did not have a significant independent effect on survival in 
this observational study. The use of steroids in the IMPI Africa 
registry, however, was not randomly allocated, and the study 
may lack sufficient statistical power to detect an effect-size of 
the magnitude found (i.e. relative reduction in mortality rate of 
39% within 6 months of diagnosis), which justifies the need for 
an adequately powered randomised controlled trial to assess 
the effect of steroids in tuberculous pericarditis.
There was a trend towards a higher mortality among 
patients from Yaoundé, Cameroon, which disappeared in the 
multivariate model. This trend could be due to a number of 
reasons. Firstly, the participants recruited in Cameroon had 
the highest rate of clinical HIV disease and disseminated 
tuberculosis.4 In addition, there could have been differences 
between the care of patients in different countries, including 
implementation of the directly observed treatment – short- 
course (DOTS) strategy17 and use of cotrimoxazole prophylaxis 
in HIV-coinfected patients, which we did not document in the 
registry.
This study has several limitations.4 Definite diagnosis 
of tuberculous pericarditis was established in only 13 
patients, with 166 participants having probable tuberculous 
pericarditis.2,4 The absence of confirmation of the diagnosis of 
pericardial tuberculosis is a major weakness of this study, as 
the mortality was particularly high among patients who had 
an alternative diagnosis. Similarly, serological confirmation 
of HIV infection was available in 96 of the 185 patients (52%). 
Among these patients, the clinical diagnosis of HIV infection 
was incorrect in 18 patients.4 However, ours was a real-life 
study which reflects the economic circumstances of medical 
practice in many African countries characterised by frequent 
shortages that, in this study, precluded HIV serological testing 
and microbiological confirmation of tuberculosis in a large 
proportion of the participants.
The findings of this study have several implications for 
clinical practice and research. The high short-term mortality 
and the significant association between mortality and an 
alternative diagnosis provide an important impetus for an 
aetiological diagnosis to be made whenever possible in patients 
with suspected tuberculous pericarditis, rather than empiric 
introduction of antituberculosis therapy.2 In addition to the 
necessity for the improvement of the specific diagnosis of 
the disease, there is also an urgent need for research on the 
appropriate timing of the introduction of antiretroviral therapy, 
and the identification of effective adjunctive treatments 
to reduce the high mortality associated with tuberculous 
pericarditis.
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